See today's BioWorld
To read the full article sign up for free or sign in.

Bluebird’s eli-cel gene therapy for CALD snatches adcom victory from jaws of defeat

June 9, 2022
By Randy Osborne
The Cellular, Tissue and Gene Therapies Advisory Committee scrutinized Bluebird Bio Inc.’s gene therapy elivaldogene autotemcel (eli-cel) for early active cerebral adrenoleukodystrophy (CALD) in patients without a matched sibling donor.
BioWorld Regulatory Endocrine/metabolic Hematologic Gene therapy U.S. FDA